
Hier werden die Strategien der Branche für das neue Jahr festgelegt!
Kostenthematik ist kurzsichtig
13 Mrz 2012 | Keine Kommentare | posted by admin | in News zur Veranstaltung, Pressestimmen
Medium: market access & health policy
Datum: 02/2012 // Seite 14-15
Autor: Jutta Mutschler
Seit einem Jahr ist das AMNOG inzwischen in Kraft. Die ersten Nutzenbewertungen liegen vor und die Preisverhandlungen beginnen. Zeit also, um ein vorläufiges Resümee zu ziehen. Die Gelegenheit dazu bot der alljährliche Branchentreff „Pharma 2012“, der von Euroforum veranstaltet wurde. …weiter lesen
G-BA official ‘sceptical’ of price-setting effectiveness assessment for established drugs
9 Mrz 2012 | Keine Kommentare | posted by admin | in News zur Veranstaltung, Pressestimmen
Medium: APM
Datum: 09.02.2012
Autor: Philippe Wackel
FRANKFURT, Feb 9 (APM) – German health insurers are preparing this year to extend the price-setting effectiveness assessment procedure to established drugs, but an official at the G-BA, the body in charge of the procedure, has expressed scepticism over these plans. “At the moment, we are sceptical,” Thomas Mueller, head of the G-BA’s pharmaceuticals department, said during the Handelsblatt Pharma conference in Frankfurt on Wednesday. …weiter lesen
Bayer Germany has mixed feelings on “Amnog”, slams lack of transparency for established drugs
9 Mrz 2012 | Keine Kommentare | posted by admin | in News zur Veranstaltung, Pressestimmen
Medium: APM
Datum: 09.02.2012
Autor: Philippe Wackel
FRANKFURT, Feb 9 (APM) – Bayer Healthcare Germany’s manager Liam Condon has mixed feelings on the implementation of the “Amnog” price-setting effectiveness assessment procedure so far and has called for increased transparency on how the procedure is implemented for established drugs. Speaking at the Handelsblatt pharma conference in Frankfurt on Wednesday,
Condon said he wished to have more details on the timetable and the way the authorities’ plan to extend the price-setting effectiveness evaluation to medicines already on the market. …weiter lesen



Prof. Dr. Dr.